Occupational Health & Safety Risks: What’s at Stake?
- A major clinical trial,the SELECT trial,has revealed a potential increased risk of cardiovascular events - including heart attack,stroke,and cardiovascular death - in individuals with obesity and established cardiovascular...
- The SELECT trial specifically focused on adults with obesity (BMI of 27 or higher) *and* pre-existing cardiovascular disease, such as heart attack, stroke, or peripheral artery disease.Participants were...
- The absolute risk increase was relatively small - approximately 1.3 cardiovascular events per 100 person-years.
ozempic adn Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial,the SELECT trial,has revealed a potential increased risk of cardiovascular events - including heart attack,stroke,and cardiovascular death – in individuals with obesity and established cardiovascular disease who where treated with semaglutide (Ozempic). The study, involving over 17,600 participants, showed a statistically significant, though relatively small, increase in these events compared to a placebo group. This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Understanding the SELECT Trial: key Details
The SELECT trial specifically focused on adults with obesity (BMI of 27 or higher) *and* pre-existing cardiovascular disease, such as heart attack, stroke, or peripheral artery disease.Participants were randomly assigned to recieve either 2.4 mg of semaglutide weekly or a placebo, along with their standard cardiovascular care. The primary outcome was the first occurrence of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or unstable angina requiring hospitalization. Over an average of 3.4 years, the semaglutide group experienced a 9% increased risk of these events.
| Outcome | Semaglutide Group (n=8831) | Placebo Group (n=8801) | Hazard Ratio (95% CI) |
|---|---|---|---|
| Cardiovascular Death | 3.7% | 2.1% | 1.74 (1.11 to 2.73) |
| Nonfatal Myocardial Infarction | 2.6% | 1.9% | 1.33 (0.83 to 2.13) |
| Nonfatal Stroke | 3.7% | 3.0% | 1.22 (0.80 to 1.85) |
| Unstable Angina Requiring Hospitalization | 1.2% | 0.8% | 1.48 (0.74 to 2.96) |
What Does This Mean? Separating Risk and Benefit
It’s crucial to avoid overreaction. The absolute risk increase was relatively small – approximately 1.3 cardiovascular events per 100 person-years. Though, the statistical meaning of the finding warrants careful consideration. Semaglutide remains highly effective for weight loss and improving metabolic health, but this trial highlights that its benefits may not outweigh the risks in *all* patient populations. The trial does *not* suggest a problem for individuals using semaglutide for diabetes management, or for those with obesity *without* pre-existing cardiovascular disease.